120 related articles for article (PubMed ID: 38361210)
1. CD14
Zhou J; Xiao H; Wang Z; Wang H; Liang X; Zhai Z; Hong J
Immunol Cell Biol; 2024 Apr; 102(4):256-268. PubMed ID: 38361210
[TBL] [Abstract][Full Text] [Related]
2. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.
Marini O; Spina C; Mimiola E; Cassaro A; Malerba G; Todeschini G; Perbellini O; Scupoli M; Carli G; Facchinelli D; Cassatella M; Scapini P; Tecchio C
Oncotarget; 2016 May; 7(19):27676-88. PubMed ID: 27050283
[TBL] [Abstract][Full Text] [Related]
3. The study of CD14+HLA-DR-/low myeloid-drived suppressor cell (MDSC) in peripheral blood of peripheral T-cell lymphoma patients and its biological function.
Du J; Sun X; Song Y
Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):62-67. PubMed ID: 28466815
[TBL] [Abstract][Full Text] [Related]
4. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
5. Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in B-cell non-Hodgkin's lymphoma patients.
Wang Y; Wang J; Zhu F; Wang H; Yi L; Huang K; Zhai Z
Immun Inflamm Dis; 2022 May; 10(5):e616. PubMed ID: 35478441
[TBL] [Abstract][Full Text] [Related]
6. Expansion of CD10
Fraccarollo D; Neuser J; Möller J; Riehle C; Galuppo P; Bauersachs J
Elife; 2021 Jul; 10():. PubMed ID: 34289931
[TBL] [Abstract][Full Text] [Related]
7. CD45RA expression by CD4 T lymphocytes in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD).
Jacob MC; Favre M; Lemarc'Hadour F; Sotto MF; Bonnefoix T; Sotto JJ; Bensa JC
Am J Hematol; 1992 Jan; 39(1):45-51. PubMed ID: 1531569
[TBL] [Abstract][Full Text] [Related]
8. IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.
Xiu B; Lin Y; Grote DM; Ziesmer SC; Gustafson MP; Maas ML; Zhang Z; Dietz AB; Porrata LF; Novak AJ; Liang AB; Yang ZZ; Ansell SM
Blood Cancer J; 2015 Jul; 5(7):e328. PubMed ID: 26230952
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
Lin Y; Gustafson MP; Bulur PA; Gastineau DA; Witzig TE; Dietz AB
Blood; 2011 Jan; 117(3):872-81. PubMed ID: 21063024
[TBL] [Abstract][Full Text] [Related]
10. CD14(+) HLA-DR low/(-) monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma.
Khalifa KA; Badawy HM; Radwan WM; Shehata MA; Bassuoni MA
Int J Lab Hematol; 2014 Dec; 36(6):650-5. PubMed ID: 24636145
[TBL] [Abstract][Full Text] [Related]
11. CD33
Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotyping of non-Hodgkin's lymphoma. Correlation with relapse-free survival.
Schuurman HJ; Huppes W; Verdonck LF; Van Baarlen J; Van Unnik JA
Am J Pathol; 1988 Apr; 131(1):102-11. PubMed ID: 3258475
[TBL] [Abstract][Full Text] [Related]
13. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.
Ruco LP; Pomponi D; Pigott R; Stoppacciaro A; Monardo F; Uccini S; Boraschi D; Tagliabue A; Santoni A; Dejana E
Am J Pathol; 1990 Nov; 137(5):1163-71. PubMed ID: 1700619
[TBL] [Abstract][Full Text] [Related]
14. [The expression and association of CD14(+) HLA-DR(Low/-) myeloid-derived suppressor cell-like cells and interleukin-1β in ovarian cancer].
Wang HY; Zhao R; Ren H; Zou MJ; Zhang J; Zhang Y
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2663-2669. PubMed ID: 28910953
[No Abstract] [Full Text] [Related]
15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
16. Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?
Váróczy L; Gergely L; Miltényi Z; Aleksza M; Illés A
Immunol Lett; 2005 Feb; 97(1):155-7. PubMed ID: 15626488
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology.
Schuurman HJ; van Baarlen J; Huppes W; Lam BW; Verdonck LF; van Unnik JA
Am J Pathol; 1987 Oct; 129(1):140-51. PubMed ID: 3310650
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotype predicts radiation resistance in T-lineage acute lymphoblastic leukemia and T-lineage non-Hodgkin's lymphoma.
Uckun FM; Song CW; Nesbit M; Kersey JH; Ramsay NK
Int J Radiat Oncol Biol Phys; 1992; 24(4):705-12. PubMed ID: 1429095
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin's lymphoma.
Pu LF; Li MM; Feng XJ; Zhang T; Hu LH; Zheng HM; Charwudzi A; Ding YY; Liu J; Liu ZL; Xiong SD
J Leukoc Biol; 2024 Feb; ():. PubMed ID: 38369808
[TBL] [Abstract][Full Text] [Related]
20. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
Speigl L; Burow H; Bailur JK; Janssen N; Walter CB; Pawelec G; Shipp C
Breast Cancer Res Treat; 2018 Apr; 168(2):401-411. PubMed ID: 29230664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
